Friday, August 24, 2012

PARABOLIC DRUGS LIMITED - FIRST QUARTER RESULTS - Q1 FY 2013 - NET SALES UP 63%YoY; NET PROFIT down 36% on Higher Expenditure - Future appears Promising


PARABOLIC DRUGS LIMITED

FIRST QUARTER RESULTS
Q1 FY 2013

PARABOLIC DRUGS has declared its first quarter results for Q/e June 2012 and for Year ending March,2012.

Net Sales for Q1 FY 12 stands at Rs.305.20 Cr; up by  14.72% from Q4 FY 12 (Rs.266.05 Cr); and up by      63.92% from Q1 FY 12 (Rs.186.19 Cr).

Total Expenditure    for Q1 FY 12 stands at Rs.276.04 Cr; up by  14.86% from Q4 FY 12 (Rs.240.32 Cr); and up by 78.3% from Q1 FY 12 (Rs.154.82 Cr). The expenditure has grown more than proportionately compared to Sales. Of this Material cost itself has registered Huge increase of 37% and other expenses 39% YoY.

Profit before Interest, Dep. & Taxes for Q1 FY 12 stands at Rs.29.16 Cr; up by 13.33% from Q4 FY 12 (Rs.25.73 Cr); and down by -7.04% from Q1 FY 12 (Rs.31.37 Cr). Because of heavier Expenditure, Profits YoY have come down.

Net Profit for Q1 FY 12 stands at Rs.9.76 Cr; up by 8.2% from Q4 FY 12 (Rs.9.02 Cr); and down by -35.7% from Q1 FY 12 (Rs.15.18 Cr). Net Profit is also down 36% YoY because of heavier growth in expenditure.

Diluted EPS      for Q1 FY 12 stands at Rs.1.58; compared to Rs.1.46 in Q4 FY 12; and Rs.2.45 in Q1 FY 12.

Public Shareholding stands at 60.77% in the company.

Net Profit(+)/Loss(-) from Ordinary Activities after tax  for FY 2011-12 (totally) was Rs.51.21 Cr and the Annual EPs was Rs.8.27.

52 week high/low price : Rs.42.00/16.25;

Current Price : Rs.22.80.

Considering the increase in its Sales every Quarter, the company may put up better performances in coming quarters. However, its profitability depends on  introducing more and more new products which are said to be in the pipeline and marketing them well. Thus, PDL's Future appears promising

RESULTS TABLE 

(In Lakhs.Rs)


PARABOLIC DRUGS
30-Jun-12
QoQ % Dif
31-Mar-12
YoY % Dif
30-Jun-11
31-Dec-11
30-Sep-11
Net Sales
30520
14.72
26605
63.92
18619
27089
19559
Total Expdr
27604
14.86
24032
78.3
15482
23928
16378
Profit before Interest, Dep. & Taxes
2916
13.33
2573
-7.04
3137
3161
3181
Net Profit
976
8.2
902
-35.7
1518
1282
1438
Diluted EPS
1.58
8.22
1.46
-35.51
2.45
2.07
2.32
Net Sales
30520
14.72
26605
63.92
18619
27089
19559
Changes in inventories of FG/ WIP / SIT
-2487
-310.76
1180
-61.64
-6483
-2707
-1759
Materials consumed
27149
36.62
19872
36.86
19837
13194
15724
Purchases of SIT
-

-

-
10896
-
Employee benefits
510
-16.12
608
7.82
473
593
572
Depreciation
1209
55.4
778
56
775
776
776
Other expenses
1223
-23.27
1594
38.98
880
1176
1065
Total expenses
27604
14.86
24032
78.3
15482
23928
16378
Profit  before tax
1346
10.24
1221
-32.4
1991
1696
1891
Tax Expenses
370
15.99
319
-21.78
473
414
453
Net Profit
976
8.2
902
-35.7
1518
1282
1438
Face Value (Rs )
10
0
10
0
10
10
10
Paid-up Equity
6189
0
6189
0
6189
6189
6189
Diluted EPS
1.58
8.22
1.46
-35.51
2.45
2.07
2.32
Public Shareholding (%)
60.77
-0.02
60.78
-1.68
61.81
60.83
61.31


FY 2011-12 results

Description         :               FY12 NONCON (In Lakhs of Rs)

Net Sales             :               91634
Total Expenditure            :               79784
Profit from Operations :               13058
Profit before Interest & Exceptional Items :   13058
Interest                :               6414
Profit after Interest but before Exceptional Items :   6644
Profit before tax :            6644
Tax Expense       :               1523
Net Profit            :               5121
Face Value (in Rs.)           :               10
Paid-up Equity Share Capital       :     6189
Public Shareholding (%)                :    60.78


ABOUT THE COMPANY

Parabolic Drugs Ltd., incorporated in 1996, is promoted by professionally qualified first generation entrepreneurs. It is engaged in manufacturing, including contract manufacturing, of APIs and API intermediates for domestic and international markets, including regulated markets. It manufactures Semi Synthetic Penicillin (“SSP”) and Cephalosporin range of antibiotics, whereby the product portfolio comprises 44 APIs and 7 API intermediates. The company has two manufacturing facilities located at Derabassi, Punjab and Panchkula, Haryana. It also has a custom synthesis and R&D centre at Barwala, Haryana, which started operations in January 2010. Proposed facilities include a manufacturing facility for non-antibiotic products at Chachrauli, Derabassi and another custom synthesis and manufacturing site at Panchkula being set up by PDL’s subsidiary.

NEWS ABOUT PDL

2012 :  Parabolic Drugs initiates production at its Lalru facility for lifestyle drugs and non antibiotics.The company expects to launch several molecules with a total production pipeline of  17 molecules in a 3 year period as per its Q3 FY 12 results. It is developing its distributor and stockiest network in over 20 states.

2011  :  (1) Parabolic Drugs gets Japanese nod for Cephalosporin Drugs  (2)  Parabolic Drugs receives Certificate of Suitability for Cefixime molecule from EU   (3)  Parabolic Drugs 9M FY11 net profit up 65.6% to Rs. 37.30 Crores,Sales up 24.4% to Rs. 466.04 Crores(February 2nd,2011)    (4)   Parabolic Drugs Completes first phase of Expansion

2010  :  (1)  PDL now gets EU-GMP accreditation(July 12th,2010)   (2)   Barwala Research and Development centre inaugurated

2009   :   (1)  WHO -GMP certificate for Cephalosporin facility(August 24th,2009)    (2)  ISO 14001 certification for PDL(August 6th,2010)


 *  *  *   E  N  D   *  *  *

No comments:

Post a Comment